Other efforts to mitigate CRS and potential immune therapy-related toxicities include an engineering approach to reduce glycosylation and increase sialylation of the Fc domain of the antibodies [201], including trastuzumab, which targets HER2 and is FDA-approved for the treatment of HER2+ breast cancer [202,203]. The gene discussed is ERBB2; the disease is breast carcinoma.